MENLO PARK, Calif.--(BUSINESS WIRE)--BioMap announced today a groundbreaking strategic collaboration with Sanofi to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform.

加利福尼亚州门洛帕克（BUSINESS WIRE）-BioMap今天宣布与赛诺菲开展开创性的战略合作，利用BioMap的AI平台共同开发生物治疗药物发现的尖端AI模块。

“As the largest foundational model-based approach within life sciences, we are thrilled to collaborate with Sanofi and leverage the potential of BioMap’s cutting-edge AI engine to help solve complex problems associated with new protein therapies to drive drug discovery,” said BioMap’s Chief Technology Officer, Le Song.

BioMap的首席技术官乐松说：“作为生命科学领域最大的基于模型的方法，我们很高兴与赛诺菲合作，利用BioMap尖端的AI引擎的潜力，帮助解决与新蛋白质疗法相关的复杂问题，推动药物发现。”。

“We have built what is essentially a biological map of proteins using data sets from public and private sources to inform our foundational models. Utilizing automation and integrated workflows to enhance the collection of high-quality data, we can catalyze the process of new hit discovery and lead optimization.”.

“我们使用来自公共和私人来源的数据集构建了基本上是蛋白质的生物图谱，为我们的基础模型提供信息。利用自动化和集成的工作流程来增强高质量数据的收集，我们可以催化新命中的过程发现和领先优化“。

Traditional AI methods require vast amounts of labeled data to make accurate predictions. However, in life science, labeled data are often in short supply. BioMap’s foundational models are revolutionizing AI in biology by enabling one large model, trained on ubiquitous unlabeled data, to inform multiple downstream task models.

传统的AI方法需要大量标记数据才能做出准确的预测。然而，在生命科学中，标签数据往往供不应求。BioMap的基础模型正在彻底改变生物学中的人工智能，使一个大型模型能够对无处不在的未标记数据进行训练，从而为多个下游任务模型提供信息。

This approach enables superior prediction from limited data in a range of therapeutic areas, including immunology, neurology, oncology, and rare diseases..

这种方法可以从包括免疫学，神经病学，肿瘤学和罕见疾病在内的一系列治疗领域的有限数据中进行出色的预测。。

Leveraging BioMap’s custom-built foundational models and world-leading AI expertise, as well as Sanofi’s proprietary data, computational innovations in protein engineering, and deep biologics development experience, both parties aim to create advanced AI models and protein Large Language Models that will enable biologics design and multiparametric optimization..

利用BioMap定制的基础模型和世界领先的AI专业知识，以及赛诺菲的专有数据，蛋白质工程的计算创新以及深层生物制剂开发经验，双方都致力于创建先进的AI模型和蛋白质大型语言模型，从而实现生物制剂设计和多参数优化。。

“By combining Sanofi’s proprietary data sets, digital infrastructure, AI and data science capabilities, and drug development expertise with BioMap’s protein Large Language Models, high-performance computing, and deep understanding of AI, we can optimize the process of discovery and development of breakthrough biotherapeutics,” said Matt Truppo, Global Head of Research Platforms at Sanofi.

赛诺菲全球研究平台负责人Matt Truppo说：“通过将赛诺菲的专有数据集，数字基础设施，人工智能和数据科学能力以及药物开发专业知识与BioMap的蛋白质大型语言模型，高性能计算以及对人工智能的深入理解相结合，我们可以优化发现和开发突破性生物治疗药物。

“Our collaboration with BioMap further underscores Sanofi’s commitment to becoming the first pharma company powered by artificial intelligence at scale.”.

“我们与BioMap的合作进一步强调了赛诺菲致力于成为第一家大规模人工智能制药公司。”。

Under the terms of the agreement, BioMap will receive an upfront cash payment and near-term payments for reaching module development milestones from Sanofi. BioMap will be eligible to receive payments of over $1 billion based on achievement of pre-clinical development, clinical development, regulatory, and commercial milestones..

根据协议条款，BioMap将从赛诺菲获得前期现金支付和近期支付，以达到模块开发里程碑。根据实现临床前开发，临床开发，监管和商业里程碑，BioMap将有资格获得超过10亿美元的支付。。

About BioMap

关于BioMap

Founded in 2020 by Robin Li and Wei Liu, BioMap is a disruptive life science AI company responsible for building xTrimo, the first and largest protein-centric large language model platform. Their technology allows scientists to model life more accurately, from proteins to a system level, and extract novel insights and predictions from limited data.

BioMap成立于2020年，由Robin Li和Wei Liu创立，是一家颠覆性的生命科学AI公司，负责建立xTrimo，这是第一个也是最大的以蛋白质为中心的大型语言模型平台。他们的技术使科学家能够更准确地模拟生命，从蛋白质到系统级，并从有限的数据中提取新的见解和预测。

Supported by an international, cross-functional team of over 300 experts, BioMap is solving critical, protein-related drug development problems and charting a course to radically improve patients’ lives..

在由300多名专家组成的国际跨职能团队的支持下，BioMap正在解决与蛋白质相关的关键药物开发问题，并制定一个从根本上改善患者生活的课程。。

For more information about BioMap, please visit: www.biomap.com.

有关BioMap的更多信息，请访问：www.BioMap.com。